ARAli Rahimipour

Ali Rahimipour

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ali Rahimipour has a total of 162 co-authors. Here are the top co-authors by number of shared publications:

  • Faranak Kazerouni

    Department of Medical Laboratory Sciences, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    13 shared publications
  • Faranak Kazerouni

    Department of Medical Lab Sciences, School of Allied Medical Sciences Shahid Beheshti University of Medical Sciences Tehran Iran

    11 shared publications
  • Masoud Darabi

    Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

    8 shared publications
  • Mehrnoosh Shanaki

    Department of Medical Laboratory Technology, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    8 shared publications
  • Mohammad Nouri

    Women’s Reproductive Health Research Center , Alzahra Hospital , Tabriz University of Medical Sciences, Tabriz , Iran

    7 shared publications
  • Mehrnoosh Shanaki

    Department of Medical Laboratory Sciences, School of Allied Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    6 shared publications

Latest Publications

  • Open Access

    The association study between changes in HbA1C with rs2250486 and rs67238751 genetic variants for SLC47A1 in newly diagnosed Iranian patients with type 2 diabetes mellitus: 6 months follow‐up study

    by Armina Semnani, Faranak Kazerouni, Saeid Kalbasi, Seyedeh Zahra Shahrokhi, Ali Rahimipour

    Objectives: One of the most well‐known oral medications for the treatment of T2DM is metformin. Variants have been found in studies to be useful in detecting new genes connected to T2DM aetiology and affecting metformin's mechanism of action. In this research, we aimed to study two variations of the SLC47A1 gene; rs2250486 and rs67238751, in T2DM patients who had been taking metformin for the first 6 months after the diagnosis in the Iranian population for the first time.Design and Methods: A total of 200 individuals were recruited for the study. According to their glycosylated haemoglobin (HbA1c) levels, the patients were divided into two groups: responders (HbA1c levels were reduced by at least 1% after 6 months of metformin treatment.) and non‐responders. DNA was extracted from whole blood and genotyped by Tetra ARMS PCR. High‐performance liquid chromatography (HPLC) was used to measure HbA1c levels at the start of the treatment and again 6 months later.Results: rs2250486 variant in the dominant model reduces the HbA1C levels after 6 months of metformin treatment. In fact, when compared to the T/C + C/C genotypes, the T/T genotype improves HbA1C levels (p‐value = .014). Furthermore, in the allelic model, the T allele improves HbA1C levels in comparison to the C allele (p‐value = .008). After 6 months of metformin treatment, serum levels of HbA1C in responders were reduced significantly in both groups (T/T and T/C + C/C), (p‐value = <.0001). However, the rs67238751 variant did not reveal a meaningful relationship with lower HbA1C levels in any of the models.Conclusions: This study found that the rs2250486 variant could be associated with reducing HbA1C levels while the rs67238751 variant, had no relationship.


  • Deregulation of long noncoding RNA SNHG17 and TTC28-AS1 is associated with type 2 diabetes mellitus

    by Mahroo Mohamadi, Hamid Ghaedi, Faranak Kazerouni, Maryam Erfanian Omidvar, Saeid Kalbasi, Mehrnoosh Shanaki, Ghasem Miraalamy, Ali Rahimipour

    Long noncoding RNAs (lncRNAs) have emerged as key players in several biological processes and complex diseases including type 2 diabetes mellitus (T2DM). The purpose of this study was to investigate the expression levels of SNHG17 and TTC28-AS1 in T2DM patients. Quantitative real‐time RT‐PCR analysis was performed using peripheral blood mononuclear cells (PBMCs) samples from patients diagnosed with T2DM and healthy controls. Binary logistic regression analysis was carried out to determine the odds of development of T2DM based on expression levels of lncRNAs and clinical characteristic of the subjects. Spearman’s correlation analysis was used to clarify the correlation between SNHG17 and TTC28-AS1 expressions to metabolic features. We found that SNHG17 and TTC28-AS1were down-regulated in the T2DM group compared to the healthy control group. The logistic regression revealed that body mass index (BMI), systolic blood pressure (SBP), fasting blood glucose (FBG) and TTC28-AS1 expression substantially affect T2DM susceptibility. Furthermore, expression of SNHG17 was negatively correlated with high‐density lipoprotein cholesterol (HDL‐C) and expression of TTC28-AS1 was positively correlated with low‐density lipoprotein cholesterol (LDL‐C). Decreased expressions of lncRNAs TTC28-AS1 and SNHG17 in T2DM are possibly associated with the development of T2DM.


  • Clinical significance of long noncoding RNA VIM‐AS1 and CTBP1‐AS2 expression in type 2 diabetes

    by Maryam Erfanian Omidvar, Hamid Ghaedi, Faranak Kazerouni, Saeid Kalbasi, Mehrnoosh Shanaki, Ghasem Miraalamy, Ali Zare, Ali Rahimipour

    Background/Aims: The risk of type 2 diabetes (T2D) is determined by a combination of genetic and environmental factors. Multiple studies have proposed that long noncoding RNAs (lncRNAs) are crucial molecules in regulating several biological processes and complex diseases. The study was aimed at investigating the association between the expression levels of lncRNA VIM‐AS1, lncRNA CTBP1‐AS2, and T2D susceptibility.Methods: lncRNA VIM‐AS1 and lncRNA CTBP1‐AS2 in the peripheral blood mononuclear cell (PBMC) of 100 healthy individuals and 100 T2D patients were collected for Quantitative Real‐Time RT‐PCR analysis. A logistic regression was performed to understand whether the likelihood of T2D can be predicted based on the expression levels of lncRNA VIM‐AS1 and lncRNA CTBP1‐AS2. Receiver operating characteristic (ROC) analysis was also performed to determine the statistical analysis of VIM‐AS1 and CTBP1‐AS2 levels in 200 samples.Results: Our results display that decreased levels of VIM‐AS1 and CTBP1‐AS2 in PBMC were associated with diabetes in Iranian population. The logistic regression revealed that Systolic blood pressure (SBP), low‐density lipoprotein cholesterol (LDL‐C), Fasting blood glucose (FBG) and CTBP1‐AS2 are substantial predictors of T2D. The ROC analysis of CTBP1‐AS2 revealed the area under the ROC curve (AUC) of 0.68 with a sensitivity of 58.7% and specificity of 75.3% in distinguishing nondiabetic from diabetic subjects. The ROC analysis of VIM‐AS1 determined AUC of 0.63 with a sensitivity of 56.1% and specificity of 68.37% in distinguishing the two diagnostic groups.Conclusion: lncRNA VIM‐AS1 and lncRNA CTBP1‐AS2 expression levels are associated with T2D susceptibility.


  • Long non-coding RNA LY86-AS1 and HCG27_201 expression in type 2 diabetes mellitus

    by Leyla Saeidi, Hamid Ghaedi, Mirsaber Sadatamini, Rouhollah Vahabpour, Ali Rahimipour, Mehrnoosh Shanaki, Zahra Mansoori, Faranak Kazerouni

    Long non-coding RNAs (LncRNAs) are non-coding RNAs. The potential roles of lncRNAs in type 2 diabetes mellitus (T2DM) are not well-known. In this study, we aim to assess the expression levels of LY86-AS1 and HCG27_201 in T2DM patients and a healthy control group. We obtained whole blood and serum samples from 100 T2DM and 100 non-diabetic subjects. Peripheral blood mononuclear cells (PBMCs) were extracted from whole blood samples using Ficoll. Total RNA was isolated from PBMCs obtained from patients with type 2 diabetes mellitus and healthy control individuals using TRIzol LS reagent (GeneAll Biotechnology Co., LTD.). Extracted RNA was used to synthesize complementary DNA (cDNA) with a Reverse Transcription Kit (Takara). Real-time was performed with SYBR Green (Takara) and monitored by a Rotor-Gene (Qiagen) system. We performed quantitative PCR analysis of the LY86-AS1 and HCG27_201 lncRNA expression levels in the 200 samples. Here we found that the expression of LY86-AS1 and HCG27_201 were down regulated in the T2DM group compared with the control group. We further identify that the expression of both lncRNAs was negatively correlated with fasting blood sugar (FBS) levels. Receiver operating characteristic (ROC) analysis was used to assess the diagnostic value of LY86-AS1 and HCG27_201 as biomarkers for T2DM. ROC analysis demonstrated that LY86-AS1 with an area under the ROC curve (AUC) of 0.747 (P < 0.0001, sensitivity: 64.6, and specificity: 79.8) might be the potential novel diagnostic biomarkers for T2DM. Lower expression of our two studied long non-coding RNAs LY86-AS1 and HCG27_201 in type 2 diabetes mellitus patients indicates their role in the pathogenesis of T2DM. Furthermore, LY86-AS1 could possibly be used as a diagnostic marker for T2DM.


  • High-intensity interval training (HIIT) effectively enhances heart function via miR-195 dependent cardiomyopathy reduction in high-fat high-fructose diet-induced diabetic rats

    by Soheyla Khakdan, Maryam Delfan, Maryam Heydarpour Meymeh, Faranak Kazerouni, Hamid Ghaedi, Mehrnoosh Shanaki, Fatemeh Kalaki-Jouybari, Sattar Gorgani-Firuzjaee, Ali Rahimipour

    Aims: Regarding the fact that up-regulation of miR-195 in diabetic hearts has a potential role in diabetic cardiomyopathy, the present study investigated whether continuous endurance training (CET) and high-intensity interval training (HIIT) reduces miR-195 expression and which exercise is effective in this regard. Methods: Diabetes was induced by high-fat high-fructose diet (HFHFD). Then, the rats were sub-divided into three categories; sedentary (HFHFD + SED), continuous endurance training (HFHFD + CET), and high-intensity interval training group (HFHFD + HIIT). After eight weeks of running, expression of miR-195 and myocardial function were evaluated. Results: HIIT effectively decreases the expression of miR-195 and increases the expression of Sirt1 and BCL-2 in diabetic rats compared with CET. Our results showed that HIIT compared with CET increases left ventricular ejection fraction (LVEF%) and fractional shortening (FS%). Conclusions: Our results indicated that exercise, especially HIIT is an appropriate strategy for reducing miR-195 and improving myocardial function in diabetic rats compared with CET.


  • Downregulation of long non-coding RNAs LINC00523 and LINC00994 in type 2 diabetes in an Iranian cohort

    by Zahra Mansoori, Hamid Ghaedi, Mirsaber Sadatamini, Rouhollah Vahabpour, Ali Rahimipour, Mehrnoosh Shanaki, Leyla Saeidi, Faranak Kazerouni

    Long non-coding RNAs (lncRNAs) are a subclass within the non-coding RNA repertoire that have potential roles in type 2 diabetes mellitus (T2DM). However, the biological function and molecular mechanisms of lncRNAs in T2DM remain largely unknown. The purpose of this study is to investigate the association between LINC00523 and LINC00994 expressions and T2DM susceptibility in an Iranian cohort. In this case–control study, we obtained whole blood and serum samples from 100 T2DM patients and 100 healthy subjects. We extracted peripheral blood mononuclear cells (PBMCs) from whole blood samples using Ficoll-Hypaque density-gradient centrifugation. Total RNA was extracted from the PBMC lysates by using the TRIzol-LS reagent (GeneAll). Finally, a quantitative real-time PCR (qPCR) assay was used to detect LINC00523 and LINC00994 lncRNA expression levels in the 200 samples. LINC00523 and LINC00994 expressions significantly decreased in patients with T2DM compared to the healthy participants, with a fold change for LINC00523 of 0.157 and 0.159 for LINC00994. We observed a significant inverse correlation between the expressions of these lncRNAs with FBS. Receiver operating characteristic (ROC) curve analysis revealed that LINC00523 has a higher area under the ROC curve (AUC) of 0.7430 and a lower P-value (P < 0.0001), in addition to a sensitivity of 81.44% and specificity of 61.11%. Therefore, LINC00523 could be considered a potential diagnostic biomarker for T2DM. Decreased expressions of LncRNAs LINC00523 and LINC00994 in T2DM is possibly associated with pathogenicity of T2DM in Iranian population. Moreover, LINC00523 can perhaps be considered as effective diagnostic biomarkers for T2DM.


  • Open Access

    Effect of Simultaneous Treatment with Royal Jelly and Doxorubicin on the Survival of the Prostate Cancer Cell Line (PC3): An In Vitro Study

    by Rouzbeh Mohammadi Abandansari, Hadi Parsian, Faranak Kazerouni, Roghaye Porbagher, Ebrahim Zabihi, Ali Rahimipour

    Background: Doxorubicin (DOX) therapy is the first step in the treatment of several malignancies such as prostate cancer. Drug resistance is the main drawback of this agent. Royal jelly (RJ), used to prevent or cure many diseases, is a substance produced by honey bee. Objectives: The aim of this study was to determine the cytotoxic effect of DOX and RJ on prostate cancer cells, PC3. Methods: Cell viability of the three experimental groups (RJ-treated cells, DOX-treated cells and RJ followed by DOX-treated cells) was assessed by 3-(4,5-dimethylthiazoyl-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Results: RJ-treatment increased the cytotoxic effect of DOX on PC3 cells. Namely, the effect of low dose of DOX in combination with RJ was approximately similar to that of high dose of DOX without RJ combination. Conclusions: Any natural substances that amplify the cytotoxic effect of DOX and have the potential to save normal cells can be potentially used as a therapeutic agent which can decrease the side effects of DOX-treatment. RJ has shown to play this role in the present study. Keywords: Doxorubicin; Prostate Cancer; Royall Jelly


  • Association of plasma ghrelin levels with diabetic nephropathy

    by Somayeh Rahimi, Faranak Kazerouni, Mehdi Hedayati, Mehr Ali Rahimi, Ali Rahimipour, Marjan Zarif Yeganeh, Mehrnoosh Shanaki

    Background: Ghrelin is a 28-amino acid peptide hormone which is produced in various tissues such as the kidney. It is proposed that this hormone exerts a broad spectrum of biological functions throughout the body. Ghrelin carries out endocrine and/or paracrine functions in the kidney, which seems to be one of the target tissues of this hormone. Results regarding circulating ghrelin levels in chronic kidney disease (CKD) and diabetic nephropathy (DN) patients are conflicting. We aimed to investigate the plasma ghrelin levels in type 2 diabetic patients with and without nephropathy.Methods: A total of 45 patients with DN and 45 patients with diabetes without diabetic nephropathy (NDN) were recruited for this study. Plasma ghrelin levels were determined using the enzyme-linked immunosorbent assay (ELISA) method. The association of plasma ghrelin with concentrations of fasting glucose (FBS), creatinine (Cr), blood urea nitrogen (BUN), low-density lipoprotein cholesterol (LDL), high-density lipoprotein cholesterol (HDL), triglycerides (TG) and anthropometric parameters was analyzed.Results: Plasma ghrelin concentration in the DN group was 1.16 (1.01–1.38) ng/mL and in the NDN group was 1.16 (0.92–1.41) ng/mL, so there were no significant differences between the two groups (p=0.467). In the NDN group, ghrelin showed an inverse correlation with TG (r=−0.467, p=0.001) and a direct correlation with HDL (r=0.562, p=0.000) but in the DN group these correlations were not found.Conclusions: Our findings implicated no relationship between the plasma ghrelin level and renal dysfunction in type 2 diabetic patients. Therefore, plasma ghrelin level may not be a probable indicator of kidney insufficiency in patients with type 2 diabetes mellitus (T2DM). Furthermore, we also found a positive correlation between ghrelin and HDL and an inverse correlation with TG levels.